Parallel

Parallel is a Boston-based $25M defense and dual-use venture fund investing at pre-seed, seed, and Series A. The fund’s stated focus is defense, dual-use, and AI-related infrastructure, with no disclosed healthcare sub-vertical exposure. For physician-facing digital health and clinical AI founders, this is not a healthcare investor and should not be approached as one.

The relevant adjacency for healthcare-tangent founders is dual-use technology where the same primitives serve both defense or national security customers and healthcare or biosecurity buyers. Examples could include synthetic biology tools, biosurveillance, autonomous medical logistics, ruggedized medical devices for austere environments, or AI infrastructure with bio applications. Founders building purely commercial physician AI tools or hospital workflow software will not find a fit here. Portfolio companies are not disclosed in the input record; founders considering dual-use positioning should review the firm’s current book before assuming any healthcare relevance.

Disclosed check size is $250K to $1M, with stages from pre-seed through Series A and US geographic scope. The fund is small, the bar for thesis fit is narrow, and the partnership focus is national security rather than commercial healthcare commercialization. Founders should not invest pitch effort here unless the dual-use angle is genuine and structural rather than retrofitted to win the meeting.

Named team members are not provided in the input record. The firm’s website is the primary reference for partner identification.

Approach Parallel only if you are a US founder building a dual-use technology where defense, intelligence, or national-security customers are a primary or near-primary buyer and where a healthcare or biosecurity application is a real but secondary commercial path. Physician AI tools, EHR software, billing automation, and clinical workflow companies should target healthcare-dedicated funds rather than this firm. The right entry, if a dual-use fit exists, is via a defense-tech advisor or a current SBIR or DoD program connection. When pitching, lead with the national-security mission, the customer pathway through DoD or IC, and the technology primitive, and treat any healthcare angle as secondary. Founders without an authentic defense thesis are wasting time here and should redirect to commercial healthcare investors immediately.